Summit Therapeutics Statistics Share Statistics Summit Therapeutics has 742.67M
shares outstanding. The number of shares has increased by 2.53%
in one year.
Shares Outstanding 742.67M Shares Change (YoY) 2.53% Shares Change (QoQ) 0.68% Owned by Institutions (%) 13.24% Shares Floating 111.78M Failed to Deliver (FTD) Shares 271,916 FTD / Avg. Volume 6.99%
Short Selling Information The latest short interest is 29.72M, so 4% of the outstanding
shares have been sold short.
Short Interest 29.72M Short % of Shares Out 4% Short % of Float 25.43% Short Ratio (days to cover) 9.36
Valuation Ratios The PE ratio is -57.95 and the forward
PE ratio is -27.88.
Summit Therapeutics's PEG ratio is
0.84.
PE Ratio -57.95 Forward PE -27.88 PS Ratio 0 Forward PS 1486.2 PB Ratio 32.99 P/FCF Ratio -90.17 PEG Ratio 0.84
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Summit Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.15,
with a Debt / Equity ratio of 0.02.
Current Ratio 10.15 Quick Ratio 10.15 Debt / Equity 0.02 Debt / EBITDA -0.03 Debt / FCF -0.05 Interest Coverage 0.04
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.39M Employee Count 159 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -313K Effective Tax Rate 0.14%
Stock Price Statistics The stock price has increased by -26.34% in the
last 52 weeks. The beta is -1.03, so Summit Therapeutics's
price volatility has been lower than the market average.
Beta -1.03 52-Week Price Change -26.34% 50-Day Moving Average 25.16 200-Day Moving Average 22.05 Relative Strength Index (RSI) 31.84 Average Volume (20 Days) 3,888,903
Income Statement
Revenue n/a Gross Profit -15.01M Operating Income 313K Net Income -221.31M EBITDA -212.85M EBIT -230M Earnings Per Share (EPS) -0.31
Full Income Statement Balance Sheet The company has 104.86M in cash and 7.22M in
debt, giving a net cash position of 97.64M.
Cash & Cash Equivalents 104.86M Total Debt 7.22M Net Cash 97.64M Retained Earnings -1.21B Total Assets 324.04M Working Capital 248.91M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -142.11M
and capital expenditures -139K, giving a free cash flow of -142.25M.
Operating Cash Flow -142.11M Capital Expenditures -139K Free Cash Flow -142.25M FCF Per Share -0.2
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
